trending Market Intelligence /marketintelligence/en/news-insights/trending/lb8tWCMUdK9X-2WKRwOnGA2 content esgSubNav
In This List

Mitsubishi Tanabe completes acquisition of NeuroDerm

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Mitsubishi Tanabe completes acquisition of NeuroDerm

Mitsubishi Tanabe Pharma Corp. completed the $1.12 billion acquisition of Israel-based pharmaceutical company NeuroDerm Ltd.

Under the deal, a unit of Mitsubishi Tanabe was merged with and into NeuroDerm, with the latter being the surviving corporation and a wholly owned subsidiary of the Japanese pharmaceutical company.

NeuroDerm's shareholders were entitled to receive $39 in cash per share. NeuroDerm's ordinary shares will cease to trade on the Nasdaq global market.